Long‐acting injectable paliperidone palmitate for severe anorexia nervosa and comorbid autism spectrum disorder: A case report

This case highlights the potential role of LAI paliperidone palmitate in managing treatment-refractory AN with comorbid ASD and intellectual disability, particularly in patients with poor adherence and prominent obsessive traits. Although antipsychotics are not standard for AN, LAI formulations may offer pragmatic, sustainable benefits in selected cases. Further studies are warranted to assess long-term safety and efficacy in this population.